PaySign (PAYS)
NASDAQ:PAYS
Want to see PAYS full AI Analyst Report?
Top Page
PaySign
(NASDAQ:PAYS)
Select Model
Select Model
Rating:74Outperform
Price Target:
$6.50
▲(11.30% Upside)
Action:ReiteratedDate:04/14/26
The score is driven primarily by improving financial performance (accelerating growth and margin expansion) and a strong earnings-call outlook with upbeat 2026 guidance. Technicals also support the setup with price above key moving averages, while the main offset is a relatively high P/E valuation and some operational/regulatory uncertainties mentioned on the call.
Positive Factors
Strong Revenue Growth
Sustained high revenue growth reflects meaningful market adoption of PaySign’s prepaid and patient-affordability solutions. With patient affordability scaling and guidance for 30%–35% revenue growth in 2026, the company is expanding addressable market reach and recurring fee/interchange revenue streams that support durable top-line momentum.
Negative Factors
Regulatory and Policy Uncertainty
Policy changes around co-pay accumulator/maximizer programs could alter the economics of patient-affordability products, affecting client demand and reimbursement flows. Because a core growth driver depends on payer and pharma behavior, regulatory shifts pose a persistent structural risk to revenue durability until policy clarity emerges.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained high revenue growth reflects meaningful market adoption of PaySign’s prepaid and patient-affordability solutions. With patient affordability scaling and guidance for 30%–35% revenue growth in 2026, the company is expanding addressable market reach and recurring fee/interchange revenue streams that support durable top-line momentum.
Read all positive factors
PaySign (PAYS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$320.08M
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)37.1
Beta (1Y)1.33
Revenue Growth32.61%
EPS Growth-8.26%
CountryUS
Employees173
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)0.02
Shares Outstanding55,185,394
10 Day Avg. Volume943,286
30 Day Avg. Volume1,143,353
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)5.78
Price to Sales (P/S)3.42
P/FCF Ratio5.47
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue4.15
Enterprise Value/Gross Profit8.42
Enterprise Value/Ebitda20.90
Forecast
1Y Price Target
$9.25Price Target Upside58.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.18
Revenue Forecast (FY)$108.03M
PaySign Business Overview & Revenue Model
Company Description
PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. It offers various services, such as transaction processing, cardholder enrollment, value loading, ca...
How the Company Makes Money
PaySign generates revenue primarily from operating and servicing prepaid and payment card programs. Key revenue streams typically include (1) fees earned from card programs and program management/processing services (such as platform/processing an...
PaySign Earnings Call Summary
Earnings Call Date:Mar 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call presented a strong operational and financial narrative: robust revenue growth (40.5% FY2025), material profitability improvement (net income +98%, adjusted EBITDA +107%), rapid scaling of the high-margin patient affordability business (revenue +167.8%, processed claims +79%), meaningful client savings from dynamic business rules, and positive 2026 guidance (30%–35% revenue growth). Offsetting items included lower plasma revenue per center driven by elevated inventory, a small number of center losses, a high Q4 tax rate impact, pending FDA review for the BECS product, and the need to educate the investor base about the business model. Overall, the highlights substantially outweigh the lowlights, signaling positive momentum and operating leverage heading into 2026.Positive Updates
Strong Revenue Growth
Total revenue increased 40.5% year-over-year to $82.0 million for FY2025.
Negative Updates
Pressure on Plasma Revenue per Center
Average monthly revenue per plasma center declined in 2025 due to elevated plasma inventory levels and a reduction in average donations per center despite center count growth.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Total revenue increased 40.5% year-over-year to $82.0 million for FY2025.
Read all positive updates
Company Guidance
Paysign guided 2026 revenue of $106.5M–$110.5M (30%–35% Y/Y) with plasma and pharma contributing equally and other revenue of $2.5M; gross profit margins of 60%–62%; operating expenses up ~20% (depreciation & amortization $9.5M–$10M; stock‑based comp ≈$5.5M); interest income ≈$3.1M; an expected tax rate of 22.5%–25%; net income of $13M–$16M ($0.21–$0.26 per diluted share); adjusted EBITDA $30M–$33M ($0.49–$0.53 per diluted share) on ~62.3M fully diluted shares. For Q1 2026 they expect $27M–$27.5M revenue (45.2%–47.8% Y/Y), 137 active patient affordability programs and 589 plasma centers exiting the quarter, with operating margin 20%–22%, net margin 17%–19%, adjusted EBITDA margin 34.5%–36.5%, EPS $0.07–$0.08 and adjusted EBITDA per share $0.15–$0.16, noting plasma seasonality (lowest in Q1) and pharma seasonality (highest in Q1).PaySign Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 82.03M | 58.38M | 47.27M | 38.03M | 29.46M |
| Gross Profit | 40.40M | 32.20M | 24.14M | 20.95M | 14.71M |
| EBITDA | 15.68M | 7.02M | 3.86M | 2.79M | -1.12M |
| Net Income | 7.55M | 3.82M | 6.46M | 1.03M | -2.72M |
Balance Sheet | |||||
| Total Assets | 276.25M | 179.03M | 146.60M | 108.24M | 84.05M |
| Cash, Cash Equivalents and Short-Term Investments | 21.07M | 10.77M | 16.99M | 9.71M | 7.39M |
| Total Debt | 14.03M | 2.93M | 3.31M | 3.67M | 4.01M |
| Total Liabilities | 227.76M | 148.59M | 122.11M | 91.95M | 71.06M |
| Stockholders Equity | 48.49M | 30.44M | 24.49M | 16.29M | 12.99M |
Cash Flow | |||||
| Free Cash Flow | 51.24M | 13.46M | 20.57M | 21.23M | 12.55M |
| Operating Cash Flow | 52.45M | 22.95M | 27.62M | 25.32M | 15.23M |
| Investing Cash Flow | -10.09M | -9.49M | -7.05M | -4.09M | -2.68M |
| Financing Cash Flow | 284.87K | -466.25K | -1.12M | 0.00 | 192.14K |
PaySign Technical Analysis
Positive
5.84
Price Trends
4.20
Positive
4.58
Positive
5.32
Positive
Market Momentum
0.48
Positive
66.85
Neutral
69.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAYS, the sentiment is Positive. The current price of 5.84 is above the 20-day moving average (MA) of 5.23, above the 50-day MA of 4.20, and above the 200-day MA of 5.32, indicating a bullish trend. The MACD of 0.48 indicates Positive momentum. The RSI at 66.85 is Neutral, neither overbought nor oversold. The STOCH value of 69.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PAYS.
PaySign Risk Analysis
PaySign disclosed 28 risk factors in its most recent earnings report. PaySign reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Global and regional economic conditions could harm our business. Q4, 2023
PaySign Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $320.08M | 37.12 | 17.19% | ― | 32.61% | -8.26% | |
71 Outperform | $1.77B | 27.73 | 9.84% | ― | 10.58% | -45.52% | |
69 Neutral | $479.78M | 14.08 | 22.07% | ― | -6.57% | -29.62% | |
66 Neutral | $2.11B | 82.10 | 7.96% | ― | 24.71% | 99.52% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
51 Neutral | $275.49M | -1.22 | -17.60% | ― | -0.58% | -57.43% | |
47 Neutral | $282.39M | -0.40 | -139.50% | ― | 101.97% | 58.61% |
* Technology Sector Average
PAYS
PaySign
5.84
3.67
169.12%
IMXI
International Money Express
15.86
3.76
31.07%
RPAY
Repay Holdings
3.18
-1.18
-27.06%
AVPT
AvePoint
9.97
-4.06
-28.97%
PAYO
Payoneer
5.17
-0.98
-15.93%
BKKT
Bakkt Holdings, Inc. Class A
9.56
0.86
9.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.